Abstract
In 1956, (±)-thalidomide was introduced into the market in Europe as sedative and drug for morning sleeping sickness which resulted into a tragedy called thalidomide tragedy (softenon drama) due to its teratogenic effects in newly born babies. Thalidomide was banned all over the world due to this havoc, which was a big breakdown in the history of this drug. But, in 1998 it resurged after US, FDA approved it for treating Erythema Leprosum Nodosum (ENL). Besides, recently thalidomide and its derivatives showed remarkable property for controlling several malignancies. Thalidomide and its analogues have been used for treating metastatic prostate cancer, multiple myeloma, HIV-related ulcers, Kaposi's sarcoma, weight loss and body wasting associated with HIV. The present article describes the sate-of-art of thalidomide applications with special emphasis on pharmacology, pharmacokinetics, breakdown in the history, break through and resurgence, potential future anticancer drug, potencies of thalidomide vs its analogues, mechanism of anticancer action, different stages and toxicity management. Besides, efforts were also made to predict the future perspectives of thalidomide and its analogues.
Keywords: Anticancer drugs, break down and resurgence, future perspectives, mechanism of action, thalidomide, thalidomide analogues
Current Drug Therapy
Title:Thalidomide: A Banned Drug Resurged into Future Anticancer Drug
Volume: 7 Issue: 1
Author(s): Imran Ali, Waseem A. Wani, Kishwar Saleem and Ashanul Haque
Affiliation:
Keywords: Anticancer drugs, break down and resurgence, future perspectives, mechanism of action, thalidomide, thalidomide analogues
Abstract: In 1956, (±)-thalidomide was introduced into the market in Europe as sedative and drug for morning sleeping sickness which resulted into a tragedy called thalidomide tragedy (softenon drama) due to its teratogenic effects in newly born babies. Thalidomide was banned all over the world due to this havoc, which was a big breakdown in the history of this drug. But, in 1998 it resurged after US, FDA approved it for treating Erythema Leprosum Nodosum (ENL). Besides, recently thalidomide and its derivatives showed remarkable property for controlling several malignancies. Thalidomide and its analogues have been used for treating metastatic prostate cancer, multiple myeloma, HIV-related ulcers, Kaposi's sarcoma, weight loss and body wasting associated with HIV. The present article describes the sate-of-art of thalidomide applications with special emphasis on pharmacology, pharmacokinetics, breakdown in the history, break through and resurgence, potential future anticancer drug, potencies of thalidomide vs its analogues, mechanism of anticancer action, different stages and toxicity management. Besides, efforts were also made to predict the future perspectives of thalidomide and its analogues.
Export Options
About this article
Cite this article as:
Ali Imran, A. Wani Waseem, Saleem Kishwar and Haque Ashanul, Thalidomide: A Banned Drug Resurged into Future Anticancer Drug, Current Drug Therapy 2012; 7 (1) . https://dx.doi.org/10.2174/157488512800389164
DOI https://dx.doi.org/10.2174/157488512800389164 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-EGFR-mAb and 5-Fluorouracil Conjugated Polymeric Nanoparticles for Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Editorial: Brain Imaging and Automatic Analysis in Neurological and Psychiatric Diseases – Part II
CNS & Neurological Disorders - Drug Targets Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Cyclodextrins and their Derivatives as Carrier Molecules in Drug and Gene Delivery Systems
Current Organic Chemistry RGD Peptide–mediated Molecular Imaging for Targeting Integrin Alpha(v) Beta(3) in Tumors: A Review
Current Medical Imaging NRG1-ErbB Lost in Translation: A New Paradigm for Lung Cancer?
Current Medicinal Chemistry Identifying Endogenous Neural Stem Cells in the Adult Brain In Vitro and In Vivo: Novel Approaches
Current Pharmaceutical Design Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry Computer-Aided Drug Design Applied to Secondary Metabolites as Anticancer Agents
Current Topics in Medicinal Chemistry Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Current Drug Targets Computational Insights into the Role of Glutathione in Oxidative Stress
Current Neurovascular Research Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design Role of Gap Junction Channel in the Development of Beat-to-Beat Action Potential Repolarization Variability and Arrhythmias
Current Pharmaceutical Design Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer
Current Chemical Biology Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Antiviral Drugs that Target Cellular Proteins May Play Major Roles in Combating HIV Resistance
Current Pharmaceutical Design Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Current Molecular Pharmacology Studies on Chloride Channels and their Modulators
Current Topics in Medicinal Chemistry